IP Library › Granted Patent US 10,076,539
Granted Patent B2
US 10,076,539 · App. 15/625,300 · Granted Sep 18, 2018

Pharmaceutical use of potassium hydroxide

Inventor: Zhibao Wang (Hefei, CN)
A61K33/00A61K9/0014A61K9/0053A61K9/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,076,539
App. No.
15/625,300
Granted
Sep 18, 2018
Kind
B2
Abstract

This relates to the pharmaceutical use of KOH, in forms of topical, oral drugs or intravenous drip, prepared for treating high blood uric acid, especially gout. The external application refers to footbath in soaking solution or embrocation on attack position. The action of the drugs is also to promote the excretion of uric acid. Compared with colchicine and other drugs, KOH has three notable features. First, it takes effect quickly. No matter being applied by footbath, oral or embrocation, it can relieve symptoms within ten minutes, and the pain during gout attack will be significantly reduced. Second, it takes curative effect quickly. After application of the drugs for 2-3 consecutive days, gout symptoms will completely disappear. Third, it has no side effects. In one respect, with a low concentration, the KOH will not corrode the skin. In a further respect, potassium ion itself is diuretic and it has no harm to kidney.

Claims (3)

1. A method of lowering blood uric acid in a human subject for gout treatment comprising the step of: administering a drug composition of potassium hydroxide to the human subject, wherein the drug composition is a soaking solution for external use and the potassium hydroxide has a concentration of 0.01-0.05 mol/L.

2. A method of lowering blood uric acid in a human subject for gout treatment comprising the step of: administering a drug composition of potassium hydroxide to the human subject, wherein the drug composition is an embrocation for external use and the potassium hydroxide has a concentration of 0.1-0.5 mol/L.

3. A method of lowering blood uric acid in a human subject for gout treatment comprising the step of: administering a drug composition of potassium hydroxide to the human subject, wherein the drug composition is an injection solution and the potassium hydroxide has a concentration of 1-10 μmol/L.

Priority Claims (1)
CN 2016 1 0451115 · Jun 17, 2016 · national
Continuity (1)
Related Publication 20170360827A1 · Dec 21, 2017
Cited By (1)
US 12,310,983